Oral agent for improving allergic dermatitis

An oral preparation with plasmalogen extracted from animal tissues addresses the delivery challenge by reducing mast cell numbers in the dermis, effectively treating allergic dermatitis.

JP7579605B2Active Publication Date: 2024-11-08INST OF RHEOLOGICAL FUNCTION OF FOOD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023100591
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-06-20
Publication Date
2024-11-08
Estimated Expiration
2041-02-15

AI Technical Summary

Technical Problem

Plasmalogens are not soluble in water, making it difficult to deliver them to the epidermis and dermis of the skin through the stratum corneum, and they can cause allergic reactions, limiting transdermal administration for dermatitis treatment.

Method used

An oral preparation containing plasmalogen, extracted from animal tissues such as shellfish and birds, is developed to penetrate through the stratum corneum and reduce mast cell numbers in the dermis.

Benefits of technology

The oral preparation effectively reduces mast cell numbers in the dermis, breaking the vicious cycle of itching and scratching associated with allergic dermatitis, thereby improving symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579605000004
    Figure 0007579605000004
  • Figure 0007579605000005
    Figure 0007579605000005
  • Figure 0007579605000006
    Figure 0007579605000006
Patent Text Reader

Abstract

To provide a topical preparation for improved skin allergy as a new use for plasmalogens.SOLUTION: A topical preparation for improved skin allergy contains plasmalogens.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an oral preparation containing a plasmalogen for improving allergic dermatitis. [Background technology]

[0002] Allergic dermatitis refers to eczema dermatitis that develops due to allergic inflammation, and representative diseases include contact dermatitis, which is a delayed type of allergic inflammation, and atopic dermatitis, which is an immediate and delayed type of allergic inflammation. Both types of dermatitis involve IgE and mast cells, which are produced locally in response to the invasion of allergens. In particular, IgE binds to mast cells and releases histamine, an itching mediator, by degranulation. Furthermore, mast cells that have degranulated at the site of inflammation recover, store granules again, and degranulate again. Such degranulation of mast cells not only induces immediate itching, but also causes a vicious cycle of itching and scratching (Non-Patent Document 1).

[0003] The main focus of treatment for allergic dermatitis is to maintain a healthy living environment, including antigen avoidance, and long-term symptomatic treatment using anti-inflammatory drug therapy. Therefore, the aim is to improve the patient's quality of life by preventing the onset and aggravation of the disease (Non-Patent Document 2), and it is desirable to take measures to enable patients to receive continuous medical care and to manage themselves. In this situation, therapeutic intervention using anti-IgE antibodies that inhibit the binding of IgE to mast cells has been established for some patients for whom existing drugs do not produce therapeutic effects.

[0004] On the other hand, plasmalogen is a type of ether-type phospholipid and has a vinyl ether bond. It is known that in humans, it is present in large amounts in the nervous, cardiovascular, and immune systems. It has been known that plasmalogen has an anti-central nervous system inflammation effect (Patent Document 1). Furthermore, it has been reported that plasmalogen has an excellent effect on improving fatty liver (Patent Document 2), and that plasmalogen improves memory function in patients with mild Alzheimer's disease who have been orally administered the drug (Non-Patent Document 3).

[0005] In addition, 1-alkyl ether type phospholipids extracted from krill, which is considered particularly preferable for the reasons that "the 1-alkyl ether type phospholipid content in ether type phospholipids is high and the plasmalogen content is extremely low, i.e., it is a natural product with a high ratio of 1-alkyl ether type phospholipid content in ether type phospholipids, and furthermore, the living body itself can be used as a direct extraction source without separating tissues, so it is abundant and easy to obtain, and furthermore, since it contains astaxanthin, it is possible to obtain a dermatitis improving / preventing agent with good storage stability (Patent Document 3, paragraph 0012)", have been reported as "a pharmaceutical composition that can effectively prevent or treat dermatitis, particularly atopic dermatitis, and a food and drink composition for preventing or improving dermatitis (Patent Document 3, paragraph 0001)" because, when administered orally, "it is possible to reduce the IgE concentration in the blood and improve the symptoms of dermatitis (Patent Document 3, paragraph 0037)". [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Retable 2012 / 03947 [Patent Document 2] Patent application 2020-063818 [Patent Document 3] Patent 6755530 [Non-patent literature]

[0007] [Non-Patent Document 1] Medical Society Newspaper No. 2498 2002 [Non-Patent Document 2] Ministry of Health, Labor and Welfare 2019 10-year strategy for immunological and allergic diseases (http: / / www.mhlw.go.jp / newinfo / kobetu / kenkou / ryumachi / index.html) [Non-Patent Document 3] Fujino T et al, Efficacy and Blood Plasmalogen Changes by Poral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Doulble-blind, Placebo-controlled Trial” EBiomedicine,

[17] (2017) 199-205 Summary of the Invention [Problem to be solved by the invention]

[0008] As described above, various pharmacological effects of plasmalogen have been reported. However, because plasmalogen is insoluble in water, it is difficult to deliver it to the epidermis and dermis of the skin through the stratum corneum, and no studies have been conducted on its transdermal administration for allergic dermatitis.

[0009] An object of the present invention is to provide an oral preparation for improving allergic dermatitis as a new use of plasmalogen. [Means for solving the problem]

[0010] The inventors discovered that plasmalogen penetrates from the epidermis to the dermis of the skin via the stratum corneum and reduces the number of mast cells present in the dermis, and through further research, they have completed the present invention.

[0011] That is, the present invention is as follows. [1] An oral agent for improving allergic dermatitis, characterized by containing plasmalogen. [2] The oral preparation for improving allergic dermatitis according to the above [1], wherein the oral preparation contains the plasmalogen in an amount of 0.1% by mass to 10% by mass based on the total amount of the oral preparation. [3] The oral preparation for improving allergic dermatitis according to the above [1] or [2], wherein the plasmalogen is a plasmalogen extracted from animal tissue. [4] The oral preparation for improving allergic dermatitis according to the above [3], wherein the animal tissue is tissue of an animal selected from the group consisting of shellfish, sea squirts and birds. [5] The oral preparation for improving allergic dermatitis according to the above [3] or [4], wherein the animal tissue is scallop tissue. Effect of the Invention

[0012] The oral preparation for improving allergic dermatitis of the present invention has an excellent effect of improving allergic dermatitis. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 shows a method for separating plasmalogen for use in a composition for improving allergic dermatitis by HPLC and a chart of purified plasmalogen (Example 1). [Diagram 2] FIG. 2 shows the number of mast cells in the dermis of mice to which a plasmalogen-containing skin ointment and a control ointment were applied (Example 2). [Diagram 3] FIG. 3 shows the number of mast cells in the dermis of NC / Nga mice fed a control diet and a diet containing plasmalogen (Comparative Example 1). [Figure 4] Figure 4 shows the effect of plasmalogen-containing ointment on atopic dermatitis in Example 3. In Figure 4, A) shows typical results of the skin of a mouse to which white petrolatum was applied, and B) shows typical results of the skin of a mouse to which plasmalogen-containing ointment was applied (Example 3). [Diagram 5] FIG. 5 shows the effect of a plasmalogen-containing ointment on redness and bleeding due to atopic dermatitis as determined in Example 3 (Example 3). [Figure 6] FIG. 6 shows the effect of a plasmalogen-containing ointment on crust formation and drying in Example 3. (Example 3) DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The composition for improving allergic dermatitis of the present invention is characterized by containing a plasmalogen. The allergic dermatitis in the present invention means eczema dermatitis caused by allergic inflammation due to the invasion of allergens, including contact dermatitis and atopic dermatitis. The allergic dermatitis improvement is the concept of recovering from eczema dermatitis. The composition for improving allergic dermatitis of the present invention can prevent the occurrence of itching caused by the invasion of allergens into the skin. That is, it can also be used as a composition for preventing eczema dermatitis.

[0015] Plasmalogens are a subclass of glycerophospholipids characterized by a vinyl ether bond at position 1 (sn-1) of the glycerol backbone and are found in high concentrations in the plasma membranes of cells that compose many mammalian tissues.

[0016] The plasmalogen used in the present invention is not particularly limited as long as it is generally classified as a plasmalogen, but examples thereof include choline-type plasmalogens, ethanolamine-type plasmalogens, inositol-type plasmalogens, and serine-type plasmalogens. Among these, choline-type plasmalogens and ethanolamine-type plasmalogens are preferred, and ethanolamine-type plasmalogens are particularly preferred.

[0017] The plasmalogen of the present invention can be extracted from animal tissue. The animal tissue is not particularly limited as long as it contains plasmalogen, and examples thereof include aquatic animals such as shellfish, sea squirts, sea cucumbers, salmon, pacific saury, and bonito, and birds. Among these, shellfish, sea squirts, and birds are preferred, and shellfish are particularly preferred. Edible parts (edible parts) are preferred as the parts to be used. These animal tissues may be cut, but it is preferable to use pulverized parts because plasmalogen can be extracted more efficiently.

[0018] Examples of shellfish include edible bivalve shells and gastropods such as scallops, mussels, and abalone, with scallops being particularly preferred. Scallops are edible bivalve shells belonging to the Pectinidae family, and examples of such shells include those belonging to the Mizuhopecten and Pecten genera. Specific examples include scallops (scientific name: Mizuhopectenyessoensis) harvested in Japan and European scallops (scientific name: Pectenmaximus (Linnaeus)) harvested in Europe. Edible parts include the adductor muscle and string (mantle, genital vein, pennant membrane), etc.

[0019] Sea squirts are edible chordates belonging to the family Halocynthidae, including the genera Halocynthia and Halocynthia. Specifically, Halocynthia roretzi (scientific name) and Halocynthia aurantium (scientific name) can be mentioned. The edible part can be the flesh (fascia).

[0020] The bird is not particularly limited as long as it is an edible bird, and examples thereof include chickens, silkie chickens, ducks, etc. As the edible part, breast meat, which is rich in plasmalogen, is preferable.

[0021] Extraction of plasmalogen can be performed using water, an organic solvent, or a water-containing organic solvent, and is preferably performed in combination with an enzyme treatment. For example, ethanol extraction and hexane extraction are possible, with hexane extraction being preferred.

[0022] The hexane extraction method is not particularly limited as long as it is a method of extraction using hexane, and examples thereof include the methods described in REP 2009-154309 and REP 2008-146942.

[0023] The ethanol extraction method is not particularly limited as long as it is a method of extraction using ethanol (including aqueous ethanol), and examples thereof include the methods described in JP 2019-140919 A, JP 2018-130130 A, JP 2012-039472 A, JP 2010-065167 A, and JP 2010-063406 A.

[0024] The composition of the present invention can be used, for example, as a cosmetic ingredient whose efficacy has been approved by a designated organization, such as a pharmaceutical product (including quasi-drugs) or an external skin preparation.

[0025] The composition of the present invention can be used as a skin external preparation or an injection. The skin external preparation is not particularly limited as long as it is applied to the skin, and examples of the form of the skin external preparation include ointments, creams, gels, lotions, emulsions, packs, and compresses.

[0026] The content of plasmalogen in the composition of the present invention may be appropriately determined within the range in which the effect is exhibited. Although it depends on the form, for example, the plasmalogen is preferably 0.1% by mass or more of the total composition of the present invention in terms of dry mass, and particularly preferably 1.0% by mass or more. Even if the total composition is 10% by mass or more, the effect is not impaired, but it is not practical from the viewpoint of cost.

[0027] The composition of the present invention can be manufactured by known methods by adding other components other than the components, within the scope that does not impair the effect of the present invention.Other components other than the components of the present invention can be, for example, other drugs, vitamins, minerals, proteins, peptides, amino acids, animal oils, and vegetable oils.In addition, it can contain water, lower alcohols, film agents, moisturizers, UV absorbers, sterilizers, preservatives, pH adjusters, etc., which are applied to skin coating agents.

[0028] As part of a research project to develop applications for plasmalogen, a skin ointment containing plasmalogen was applied to the skin of mice. The skin from the applied area was collected, and the mast cells in the skin sections were stained with a toluidine blue solution to compare the changes in the number of mast cells in the dermis. As a result, a significant decrease in the number of mast cells in the dermis was observed after application of the plasmalogen-containing skin ointment. This means that, unlike conventional antihistamines that inhibit the binding of histamine to H1 receptors and suppress itching, plasmalogen is expected to eliminate mast cells from the lesion and interrupt the vicious cycle of itching and scratching, in allergic dermatitis, including atopic dermatitis, which is caused by the release of histamine due to degranulation of mast cells. In addition, it is expected to be effective against itching induced by tryptase, an enzyme in mast cells that cannot be suppressed by antihistamines. Therefore, we decided to investigate this in detail.

[0029] The present invention will now be described in more detail with reference to examples. The present invention is not limited to the following examples. EXAMPLES

[0030] [Preparation of plasmalogen for improving allergic dermatitis] Plasmalogen for improving allergic dermatitis was extracted from scallops and chicken breast using hexane, for example, using the method described in Publication No. 2016 / 181491. The main steps for extracting plasmalogen from scallops are shown below. 1. Scallops were added with coagulase P (manufactured by Mitsubishi Chemical Foods Corporation) and phospholipase A1 (PLA1) (manufactured by Mitsubishi Chemical Foods Corporation) and digested for 1 hour. 2. Next, hexane / isopropanol was added and stirred, and after standing, the supernatant was filtered by suction. 3. Aqueous sodium sulfate solution was added to the filtrate and mixed thoroughly. 4. The upper layer was evaporated to dryness using a rotary evaporator. 5. 40 mL of acetone cooled to 4°C was added to this and mixed. 6. The mixture was separated using a centrifuge at 3000 rpm for 10 min at 4°C. 7. The supernatant was discarded and the precipitate was collected. 8. Dry in a desiccator overnight. Following the procedure of Japanese Patent No. 5430566, separation was performed by HPLC using the mobile phase solvent shown in Figure 1A, and only the ethanolamine-type plasmalogen was separated as shown in Figure 1C. Note that Figure 1B shows the lipid composition in the fractions extracted in steps 1 to 8 above.

[0031] The plasmalogen extracted from chicken breast was prepared through seven steps, excluding step 5, out of the eight steps described in [Preparation of plasmalogen for improving allergic dermatitis] above. The obtained extract fraction contained two types of plasmalogen, ethanolamine type and choline type, and cholesterol, as described in REP 2016 / 181491. EXAMPLES

[0032] [Effects of plasmalogen-containing skin application] The plasmalogen-containing skin application agent was prepared by dissolving 51 mg of plasmalogen extracted from scallops and 5 mg of a fraction extracted from chicken breast (plasmalogen content 9.1% by mass) in 3.64 ml of ethanol, then adding 1.56 ml of distilled water to obtain 5.2 ml of plasmalogen solution. The control application agent was prepared in the same manner as the plasmalogen-containing skin application agent, but without dissolving the plasmalogen.

[0033] Seven-week-old male C3H mice were purchased from KBT Oriental Co., Ltd. At the age of 8 weeks, the hair on the dorsal skin was shaved with an electric animal clipper, then removed with hair removal cream, and randomly divided into a plasmalogen-containing skin ointment group (n=5) and a control ointment group (n=5) to which only 70% ethanol was applied. Application was started 48 hours after shaving. The ointment was 20 μl / cm 2 The hair was removed and the treatment was continued for 4 weeks, 5 times a week. Food and water were available ad libitum during the breeding period.

[0034] After the test, mice from each group were euthanized under deep anesthesia, and the skin from the application site was collected. It was immediately chemically fixed in paraform solution according to the usual method, and then paraffin sections were prepared. A total of 20 discontinuous sections were randomly extracted from five mice from each group, and the mast cells in the skin sections were stained with toluidine blue solution (pH 4.1).

[0035] The number of mast cells in the skin on the backs of mice in the control and plasmalogen-containing skin application groups was converted to 1mm x 1mm of skin and is shown in Figure 2. As a result, the plasmalogen-containing skin application group showed a statistically significant (p<0.05, Student's t-test) decrease in the number of mast cells in the skin compared to the control application group. Therefore, it was clearly demonstrated for the first time that plasmalogen dissolved in ethanol penetrates the epidermis when applied to the skin surface, reaches the dermis below, and reduces the number of mast cells in the dermis. Comparative Example 1

[0036] [Effect of oral administration of plasmalogen on the distribution of mast cells in the dermis] Oral plasmalogen was prepared from scallops following steps 1 to 8 of the above [Preparation of plasmalogen for improving allergic dermatitis].

[0037] Six-week-old male Nc / Nga mice were purchased from KBT Oriental Co., Ltd. and divided into two groups. Only one group was fed with food containing 0.1% by weight of plasmalogen and allowed to orally ingest plasmalogen for 12 weeks. Next, skin sections from the affected area of ​​atopic dermatitis on the back were prepared by the method described in Example 2, and the distribution of mast cells in the dermis was examined. During the breeding, food and water were freely available.

[0038] As shown in Figure 3, no difference was found in the number of mast cells in the dermis between mice that orally ingested plasmalogen (4 mice) and mice that did not (3 mice). EXAMPLES

[0039] [Effects of plasmalogen-containing ointment on atopic dermatitis] Therefore, the effect of plasmalogen-containing ointment on atopic dermatitis was examined in an experimental mouse model of atopic dermatitis.

[0040] Plasmalogen for ointment was prepared from scallops following steps 1 to 8 described in [Preparation of plasmalogen for improving allergic dermatitis] above. To prepare the plasmalogen-containing ointment, the extracted plasmalogen was dissolved in ethanol and mixed with the base material, white petrolatum, at a temperature of 40°C or less. The ethanol was removed by spraying nitrogen gas to prepare an ointment containing 5% plasmalogen. The ointment was stored at 4°C.

[0041] The effect of plasmalogen-containing ointment on atopic dermatitis was examined using a mouse model of atopic dermatitis caused by the dust mite (Dematophagoides farina: Df), an allergen in atopic dermatitis. The mice were allowed free access to food and water during breeding.

[0042] Six-week-old male Nc / Nga mice were purchased from KBT Oriental Co., Ltd. At the age of 7 weeks, the hair on the dorsal skin was shaved with an electric animal clipper, then removed with a hair removal cream, and randomly divided into three groups (8 individuals each) as shown in Table 1. The component derived from D. farinae was applied twice a week for three weeks. The first time, 100 mg of the component derived from D. farinae (product name: Biosta AD, Biosta Co., Ltd.) was applied after hair removal. From the second time onwards, 150 μl of 4% sodium dodecyl sulfate was evenly applied to the shaved area, and after natural drying, 100 mg of the component derived from D. farinae was applied.

[0043] [Table 1]

[0044] Figures 4A and 4B show typical results of the skin condition during the experimental course of mice in groups B and C. The dorsal skin of mice in groups B and C, to which components derived from D. farinae were applied for three weeks, showed localized redness and peeling of keratin.

[0045] Next, all mice in Group A, which did not receive the component derived from D. farinae, and Groups B and C were visually inspected for symptoms characteristic of atopic dermatitis, including redness, bleeding, crust formation, and dryness. Redness and bleeding were assessed using the indicators shown in Table 2, and crust formation and dryness were assessed using the indicators shown in Table 3. The condition of each mouse was scored on a 4-point scale, with 0 being no symptoms and 3 being severe.

[0046] [Table 2]

[0047] [Table 3]

[0048] Figure 5 is a graph showing the average scores for the degree of redness and bleeding in the affected areas of atopic dermatitis in eight mice in each group, based on Table 2. At the completion of application of the component derived from Dermatophagoides farinae, the symptoms of redness and bleeding in the dorsal skin of the mice in groups B and C became more severe compared to group A, which did not receive the component, and the changes were statistically significant (††p<0.01 and †p<0.05), respectively.

[0049] Figure 6 shows the average score based on Table 3 for the degree of crust formation and dryness at the site of atopic dermatitis in eight mice from each group. At the completion of application of the component derived from D. farinae, the symptoms of crust formation and dryness in groups B and C became more severe compared to group A, which did not receive the component, and the changes were statistically significant in both groups (††p<0.01). These results demonstrate that a mouse model of atopic dermatitis caused by the component derived from D. farinae was established, making it possible to verify the recovery of symptoms by plasmalogen ointment.

[0050] To verify the effect of plasmalogen-containing ointment on atopic dermatitis, two earpick-sized spoonfuls of plasmalogen-containing ointment were applied to mice in group C, which had developed atopic dermatitis, five times a week for four weeks. White petrolatum was applied to mice in group B, which had developed atopic dermatitis, at the same frequency. If hair was present at the time of each application, it was carefully cut with clippers to avoid irritating the skin. In addition, the skin symptoms were photographed every week with a digital camera.

[0051] Figure 4 shows typical skin symptoms 3 and 4 weeks after the start of application in mice in group B, which received white petrolatum, and group C, which received plasmalogen-containing ointment. As shown in Figure 4A, redness and peeling of keratin were observed on the dorsal skin of mice in group B, which received white petrolatum. However, as shown in Figure 4B, the symptoms of redness and peeling of keratin observed on the dorsal skin of mice in group C were alleviated after application of plasmalogen-containing ointment.

[0052] Next, all mice in groups A, B, and C were visually observed, and the degree of redness / bleeding and crust formation / dryness of the dorsal skin was scored on a four-point scale from 0 to 3 every week based on Tables 2 and 3 above.

[0053] The results are shown in Figure 5. Compared to Group B, which was the group that received white petrolatum, Group C, which received the plasmalogen-containing ointment, showed a statistically significant (*p<0.05) improvement in the degree of redness and bleeding in the dorsal skin 1 and 2 weeks after application of the plasmalogen-containing ointment. In addition, as shown in Figure 6, Group C also showed a statistically significant (*p<0.05) improvement in the degree of crust formation and dryness compared to Group B.

[0054] These results indicate that percutaneous absorption of plasmalogen reduces the number of mast cells in the dermis and interrupts the vicious cycle of allergic dermatitis, which is caused by itching due to the release of histamine from mast cells and is exacerbated by scratching.

Claims

1. An oral preparation for improving allergic dermatitis, comprising a plasmalogen.

2. 2. The oral preparation for improving allergic dermatitis according to claim 1, characterized in that the oral preparation contains the plasmalogen in an amount of 0.1% by mass to 10% by mass based on the total amount of the oral preparation.

3. 3. The oral preparation for improving allergic dermatitis according to claim 1, wherein the plasmalogen is extracted from an animal tissue.

4. 4. The oral preparation for improving allergic dermatitis according to claim 3, wherein the animal tissue is selected from the group consisting of shellfish, sea squirts and birds.

5. 5. The oral preparation for improving allergic dermatitis according to claim 3, wherein the animal tissue is a scallop tissue.

Citation Information

Patent Citations

  • Internal medicine for inhibiting symptom of atopic dermatitis of type i allergic disorder

    JP2009263384A

  • Water-soluble extract of Sargassum fusiforme

    JP2018510910A

  • Composition for ameliorating fatty liver

    JP2021161062A

  • Pharmaceutical composition for preventing or treating dermatitis

    JP6755530B2

  • JPWO2012/03947A1